Session » Rheumatoid Arthritis – Etiology and Pathogenesis Poster I

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 68

A Genome-Wide Association Study Identifies rs116199914 As an Intergenic Variant Associated with Carotid Intima-Media Thickness in Spanish Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 84

ACPA-Positive Risk-RA Subject without Subclinical Arthritis Are in High Risk for Later Arthritis Onset, Especially Carriers of HLA-SE Risk-Gene

9:00AM-11:00AM: Abstract Number: 81

Additive Effects of Functional Rheumatoid Arthritis (RA) LBH Risk Alleles on LBH Gene Transcription

9:00AM-11:00AM: Abstract Number: 86

Age Dependent Effects of Cholesterol and Smoking on the Risk of Rheumatoid Arthritis in Women – Results from a Nested Case Control Study

9:00AM-11:00AM: Abstract Number: 72

Altered Serologic Responses to Epstein Barr Virus Precede Clinical Disease Development in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 82

Analysis of Intestinal Microbiome Profile of Patients with Established Rheumatoid Arthritis and Healthy Controls

9:00AM-11:00AM: Abstract Number: 85

Antibodies to Citrullinated Protein Antigens (ACPAs) Induce Adipose Tissue Dysfunction Contributing to the Cardiovascular Disease Risk in Rheumatoid Arthritis. Modulation By Biological Dmards

9:00AM-11:00AM: Abstract Number: 71

Association of Shared Epitope and Poor Prognostic Factors in RA

9:00AM-11:00AM: Abstract Number: 73

Circular RNAs Expression Profile in Chinese Rheumatoid Arthritis Patients at Different Disease Activity

9:00AM-11:00AM: Abstract Number: 70

Colocalization of Malondialdehyde-Acetaldehyde Adducts (MAA) and Extracellular Matrix Proteins in Joint and Lung Tissues from Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 78

Decreased B Cell Ataxia-Telangiectasia Mutated Expression and Receptor Diversity Identify a Subset of Rheumatoid Arthritis Patients with Increased Joint Erosion Prevalence

9:00AM-11:00AM: Abstract Number: 74

DNA Methylation of the Dual Specificity Protein Phosphatase 22 (DUSP22) Gene Promoter in Plasma of Patients with Seropositive and Seronegative RA

9:00AM-11:00AM: Abstract Number: 75

Elevated Oxylipin Profile in Autoantibody-Positive Individuals at-Risk of Developing Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 67

Intestinal Inflammation and Netosis Associate with the Presence of Stool IgA ACPA in Subjects at-Risk for RA

9:00AM-11:00AM: Abstract Number: 88

Lymphocyte DNA Methylation As a Mediator of Genetic Risk in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 69

Possible Association of Early Inflammatory Arthritis with Viral Outbreaks Such As Influenza: Time Series Analysis of the Canadian Early Inflammatory Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 80

Prediction of Future Development of Rheumatoid Arthritis in Patients with Seropositive Arthralgia

9:00AM-11:00AM: Abstract Number: 79

Rheumatoid Arthritis (RA)-Associated Autoantibodies Are Present in the Periodontal Exudate of Patients with and without RA

9:00AM-11:00AM: Abstract Number: 87

Rheumatoid Arthritis Patients with Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity

9:00AM-11:00AM: Abstract Number: 77

Single Nucleotide Polymorphism in the Gene Encoding Peptidylarginine Deiminase 4 Correlates with Reduced Neutrophil Extracellular Traps and Anti-Histone Antibodies in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 83

The Risk of Developing Rheumatoid Arthritis Based on HLA-DQ Genotypes

9:00AM-11:00AM: Abstract Number: 76

Whole Blood Targeted Bisulfite Pyrosequencing Identifies Differentially Methylated Regions within Major Histocompatibility Complex (MHC) of Patients with Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].